A2 Biotherapeutics Closes $80 Million Series C Financing to Advance Cancer Therapies

A2 Biotherapeutics, a clinical-stage cell therapy company focused on developing innovative therapies targeting cancer cells while safeguarding normal ones, has received an $80 million investment through a Series C funding round. This injection of capital, supported by investors including The Column Group and Samsara BioCapital, aims to propel the company's trio of clinical development programs and pipeline of CAR-T cell therapies, which are powered by the proprietary Tmod platform. This pioneering technology uses a dual-receptor system to distinguish tumor cells from normal tissues, taking advantage of an activator-blocker mechanism. The funding will specifically benefit the ongoing Phase 1/2 clinical trials titled EVEREST-1 and EVEREST-2. These studies concentrate on several serious cancers, employing artificial intelligence-enhanced prescreening to optimize patient selection. With roots in Agoura Hills, California, A2 Biotherapeutics is committed to advancing its treatment strategies and addressing significant unmet medical needs in oncology and beyond.